Last updated: September 2, 2026
Gadofosveset trisodium is a discontinued intravascular magnetic-resonance imaging contrast agent formerly sold as Ablavar in the United States and Vasovist in Europe. Its commercial trajectory was constrained by a narrow indication, competition from lower-cost gadolinium agents, limited hospital adoption, and withdrawal from major markets. The product has no meaningful current revenue base, no active branded growth strategy, and limited residual value outside legacy intellectual-property, regulatory, or specialty imaging applications.
What is gadofosveset trisodium used for?
Gadofosveset trisodium is a gadolinium-based contrast agent designed for contrast-enhanced magnetic resonance angiography, or CE-MRA. It binds reversibly to human serum albumin, producing prolonged intravascular residence compared with extracellular gadolinium agents.
The U.S. Food and Drug Administration approved the product as Ablavar in December 2008. The approved use was contrast-enhanced MRA to evaluate aortoiliac, renal, and peripheral vascular disease in adults. The product was administered intravenously and marketed by Lantheus Medical Imaging.[1]
In Europe, gadofosveset trisodium was sold as Vasovist. The European authorization covered contrast-enhanced MRA of abdominal or limb vessels in adults.[2]
Product and regulatory profile
| Attribute |
Gadofosveset trisodium |
| U.S. brand |
Ablavar |
| European brand |
Vasovist |
| Drug class |
Gadolinium-based MRI contrast agent |
| Imaging use |
Contrast-enhanced magnetic resonance angiography |
| U.S. approval |
2008 |
| U.S. sponsor |
Lantheus Medical Imaging |
| European authorization holder |
Bayer Schering Pharma AG |
| Administration |
Intravenous |
| Current commercial status |
Discontinued in major markets |
| Biosimilar relevance |
None |
| Generic relevance |
Limited because the reference product is no longer commercially active |
When did gadofosveset trisodium lose exclusivity?
Gadofosveset trisodium lost its commercial exclusivity position through a combination of patent aging, regulatory withdrawal, and market discontinuation rather than through a major generic launch.
The product was approved after the principal development and patent investment period had already occurred. Any composition, formulation, or use patents associated with gadofosveset trisodium would generally have had filing dates before the 2008 approval and standard 20-year terms from the earliest effective nonprovisional filing date. Patent-term adjustment, patent-term extension, and jurisdiction-specific prosecution history would determine the exact expiration dates.
No active U.S. commercial exclusivity protects a current Ablavar franchise. The FDA’s historical approval was for a branded product that is no longer a meaningful market participant. The central commercial event was product withdrawal, not a successful loss-of-exclusivity cycle.
FDA exclusivity and Orange Book position
Ablavar’s value was limited by the absence of a durable, high-volume franchise. FDA approval created regulatory market entry rights, but it did not establish a large protected market comparable with oncology, immunology, or chronic cardiovascular products.
The FDA Orange Book is relevant mainly for historical approval and patent-listing analysis. Any historical patent listing must be assessed against:
- the specific Ablavar NDA;
- the listed patents and delisting history;
- patent expiration and pediatric exclusivity;
- whether the product remained actively marketed;
- any authorized generic or abbreviated new drug application activity.
There is no current branded-market opportunity comparable with an actively marketed reference drug. A company evaluating gadofosveset trisodium today would be assessing a legacy product, not a conventional loss-of-exclusivity asset.
Why did the market for gadofosveset trisodium contract?
The product faced structural disadvantages in the MRI contrast market.
Competition from established extracellular agents
Gadofosveset competed with widely available gadolinium-based contrast agents, including gadopentetate dimeglumine, gadoterate meglumine, gadobutrol, gadoteridol, and related products. These agents were familiar to radiologists, broadly stocked by hospitals, and used across multiple MRI indications.
Gadofosveset had a differentiated pharmacologic profile, but its principal advantage was concentrated in vascular imaging. The broader agents could be used across brain, spine, musculoskeletal, abdominal, and vascular studies. That breadth supported procurement efficiency and reduced the incentive to carry a specialized product.
Limited indication breadth
Ablavar was not positioned as a general-purpose MRI contrast agent. Its principal label focused on vascular imaging, especially abdominal and peripheral vessels. The narrow indication limited utilization per hospital account and reduced the ability to spread sales and marketing costs across multiple imaging departments.
Reimbursement and hospital purchasing pressure
MRI contrast agents are commonly purchased through hospital formularies, group purchasing organizations, and radiology supply channels. A specialized product must demonstrate a clear diagnostic or workflow benefit to overcome:
- lower acquisition costs for standard agents;
- existing physician familiarity;
- inventory simplification;
- reimbursement constraints;
- contracting pressure from hospitals and purchasing groups.
The clinical differentiation of gadofosveset did not produce sufficient commercial adoption to offset these pressures.
Gadolinium safety concerns
The broader gadolinium contrast market encountered safety scrutiny involving nephrogenic systemic fibrosis and gadolinium retention. These issues affected product selection, labeling, and institutional protocols. Gadofosveset had its own renal and safety considerations and did not escape the broader category-level risk-management environment.
What was the financial trajectory of gadofosveset trisodium?
Gadofosveset trisodium did not develop into a material long-term revenue contributor for its commercial sponsors. Public company filings generally did not disclose a durable product-level revenue series for Ablavar or Vasovist. Reported financial information is therefore more useful for identifying commercial direction than for calculating a precise annual sales curve.
Commercial trajectory
| Period |
Commercial development |
Financial implication |
| 2008 |
FDA approval of Ablavar |
Entry into a specialized CE-MRA market |
| 2008 onward |
European sales under Vasovist |
Geographic expansion, but limited indication breadth |
| Early 2010s |
Competition from established MRI agents and constrained uptake |
Low scale and limited operating leverage |
| Mid-2010s |
Portfolio rationalization and declining strategic importance |
Reduced investment rationale |
| 2016-2017 |
U.S. discontinuation and European withdrawal process |
Loss of recurring branded revenue |
| Current |
No meaningful marketed franchise |
Negligible direct revenue opportunity |
Lantheus reported products such as DEFINITY and other diagnostic imaging products as more important commercial drivers than Ablavar. The company’s disclosures and subsequent portfolio priorities indicate that Ablavar did not become a core revenue engine.[3]
Bayer’s European portfolio also did not retain Vasovist as a strategic growth product. The European Medicines Agency records the withdrawal of the Vasovist marketing authorization at the request of the marketing authorization holder.[2]
Revenue exposure
Current revenue exposure is effectively zero for the original branded franchise in the United States and Europe. Any residual economics would be limited to:
- discontinued-product inventory;
- specialty or regional supply arrangements;
- intellectual-property licensing;
- regulatory file transfers;
- historical settlement or royalty arrangements;
- use of the molecule as a research or reference compound.
No public evidence supports a current multibillion-dollar or even material branded-revenue opportunity for gadofosveset trisodium.
Which companies developed and marketed gadofosveset trisodium?
The product involved several companies across discovery, development, and commercialization.
EPIX Pharmaceuticals
EPIX Pharmaceuticals developed gadofosveset as part of its blood-pool contrast-agent program. The company’s development strategy focused on albumin-binding MRI agents intended to improve vascular visualization and imaging duration.
Lantheus Medical Imaging
Lantheus commercialized the product in the United States as Ablavar. Lantheus was responsible for the U.S. regulatory and commercial franchise after approval.[1]
Bayer
Bayer commercialized the product in Europe as Vasovist through its European pharmaceutical operations. The product later underwent European authorization withdrawal.[2]
The commercial structure illustrates a common specialty-pharmaceutical risk: the asset had a technically differentiated mechanism but lacked sufficient market scale to support multiple regional commercialization organizations over time.
What patents protect gadofosveset trisodium?
The historical patent estate likely included composition-of-matter, chelate, albumin-binding, formulation, and imaging-method claims. The commercially relevant rights would have been concentrated in the United States and Europe during the product’s development and early marketing period.
Composition and chelate patents
The core patent strategy for gadofosveset-related technology would have protected:
- the gadolinium complex;
- the ligand and chelating structure;
- albumin-binding substituents;
- pharmaceutical salts, including the trisodium form;
- stereochemical or positional variants;
- methods of preparing the active pharmaceutical ingredient.
Formulation patents
Formulation protection may have covered:
- sterile aqueous injectable solutions;
- concentration ranges;
- pH control;
- excipients and stabilizers;
- container and packaging configurations;
- manufacturing processes that limit degradation or impurities.
For a contrast agent administered intravenously, formulation and manufacturing claims can be commercially relevant even when composition patents are aging. Their practical value declines rapidly after product discontinuation because there is no active branded market to defend.
Method-of-use patents
Method claims could have covered:
- contrast-enhanced MRA;
- imaging of abdominal or peripheral vessels;
- administration protocols;
- timing of image acquisition;
- use in patients with specific vascular conditions.
Method-of-use patents would have had limited value if the approved indication remained narrow and physicians could use alternative contrast agents for similar imaging procedures.
A definitive patent-expiration analysis requires linking each patent family to the relevant NDA, national phase, terminal disclaimer, patent-term adjustment, and patent-term extension records. No current commercial strategy for gadofosveset trisodium can be supported solely by historical patent rights.
Were there Paragraph IV challenges or generic launches?
There is no well-established record of a commercially consequential Paragraph IV challenge that led to a generic launch for Ablavar. The absence of a major generic event reflects the product’s limited commercial scale and subsequent discontinuation.
A generic sponsor would have faced several economic problems:
- The reference product had limited demand.
- Clinical adoption was narrower than for standard MRI agents.
- FDA approval would not guarantee meaningful hospital procurement.
- Manufacturing a sterile gadolinium injectable requires quality-system and supply-chain investment.
- The product’s commercial window had already narrowed by the time a generic could have generated scale.
The likely competitive threat was therefore substitution by existing MRI contrast agents rather than direct ANDA competition.
Is there biosimilar risk for gadofosveset trisodium?
There is no biosimilar risk. Gadofosveset trisodium is a chemically defined small-molecule gadolinium contrast agent, not a biologic. Any follow-on product would proceed through a generic-drug or other small-molecule regulatory framework, depending on the jurisdiction and product presentation.
The practical risk is also limited because no active high-value branded franchise remains. A follow-on manufacturer would be more likely to compete with other gadolinium agents than to target a commercially active Ablavar market.
What regulatory status does gadofosveset trisodium have?
United States
Ablavar received FDA approval in 2008 for CE-MRA in adults. Lantheus later discontinued the product in the United States. The product should be treated as a discontinued branded contrast agent rather than an active commercial FDA growth product.[1]
European Union
Vasovist received centralized European authorization. The European authorization was later withdrawn at the request of the marketing authorization holder. Withdrawal ended the active EU commercialization basis for the product.[2]
Other markets
The product’s status outside the United States and European Union depends on country-specific registrations, local marketing decisions, and supply records. No evidence indicates that international sales created a material offset to the U.S. and European decline.
How strong is the patent estate for gadofosveset trisodium?
The historical patent estate may have been technically meaningful but commercially weak in its current state.
| Patent-strength factor |
Assessment |
| Core composition protection |
Historically important, but likely aged |
| Formulation protection |
Potentially useful during launch years |
| Method-of-use protection |
Narrow because the approved use was specialized |
| Manufacturing protection |
Relevant to quality and cost, but difficult to monetize without demand |
| Regulatory exclusivity |
Expired or no longer commercially material |
| Current litigation leverage |
Low |
| Current licensing value |
Limited and transaction-specific |
| Generic deterrence |
Low because the reference market is discontinued |
Patent strength must be distinguished from asset value. A technically defensible patent claim does not create a viable commercial franchise when physicians, hospitals, and payers have shifted to alternative products.
What generic entry risks exist for gadofosveset trisodium?
Current generic-entry risk is low in financial significance but not because the molecule is necessarily difficult to copy. The key issue is market size.
A follow-on product could face:
- limited clinical demand;
- hospital formulary resistance;
- competition from established gadolinium agents;
- sterile manufacturing costs;
- regulatory requirements for injectable contrast products;
- uncertain access to reference-product supply and labeling history;
- weak return on development investment.
A successful generic launch would require a low-cost manufacturing model, an identifiable specialty imaging niche, or a licensing arrangement with a company holding historical regulatory data.
How does gadofosveset trisodium compare with competing MRI contrast agents?
| Factor |
Gadofosveset trisodium |
Conventional extracellular gadolinium agents |
| Primary positioning |
Vascular CE-MRA |
Broad MRI contrast use |
| Intravascular residence |
Prolonged through albumin binding |
Generally shorter |
| Indication breadth |
Narrow |
Broad |
| Hospital inventory value |
Specialized |
High across departments |
| Generic competition |
Limited |
More established |
| Current commercial status |
Discontinued in major markets |
Several active products |
| Strategic value |
Legacy or niche |
Ongoing imaging franchise value |
Gadofosveset’s clinical differentiation did not compensate for its narrower utilization and higher commercial complexity. The product was better positioned as a specialized imaging tool than as a platform contrast agent.
What licensing deals affected gadofosveset trisodium?
The asset’s development history involved partnerships and commercial arrangements associated with EPIX Pharmaceuticals, Lantheus, and Bayer. The commercially relevant transactions transferred or shared development, regulatory, and marketing rights rather than creating a durable standalone franchise.
No publicly visible current licensing structure indicates a material ongoing royalty stream from gadofosveset trisodium. Any historical royalties or milestone payments should be separated from present value because the product has been withdrawn or discontinued in its principal markets.
What is the current investment outlook for gadofosveset trisodium?
The asset has minimal conventional pharmaceutical investment value. A buyer would not be acquiring a growing branded product but a discontinued contrast-agent package with possible residual technical or regulatory utility.
Potential value could exist in:
- acquisition of historical regulatory documentation;
- reformulation or repositioning for a narrowly defined vascular-imaging use;
- licensing of albumin-binding contrast technology;
- use as a reference compound in imaging research;
- regional reintroduction where registration remains possible;
- combination with newer MRI workflow or image-analysis technologies.
These opportunities would require new clinical, regulatory, manufacturing, and commercial investment. The prior commercial record does not support a near-term revenue recovery thesis.
Key Takeaways
- Gadofosveset trisodium was marketed as Ablavar in the United States and Vasovist in Europe.
- FDA approval occurred in 2008 for contrast-enhanced MRA of selected vascular territories.
- The product’s principal weakness was limited indication breadth against broadly used gadolinium agents.
- Lantheus and Bayer did not develop the product into a durable, material revenue franchise.
- U.S. and European commercialization ended after portfolio rationalization and authorization withdrawal.
- No significant current biosimilar or Paragraph IV threat exists.
- Historical patents may have covered composition, formulation, manufacturing, and vascular-imaging methods, but current patent value is limited.
- Present direct revenue exposure is effectively negligible in the major markets.
- Any residual value is more likely to arise from licensing, regulatory-file transfer, or technology reuse than from branded sales.
FAQs
Is gadofosveset trisodium still available in the United States?
Ablavar, the U.S. brand for gadofosveset trisodium, was discontinued and is not a meaningful current U.S. commercial product.
What company owned Ablavar?
Lantheus Medical Imaging commercialized Ablavar in the United States after FDA approval.
Was Vasovist approved by the FDA?
No. Vasovist was the European brand. The U.S. product was marketed as Ablavar.
Can gadofosveset trisodium be replaced by gadobutrol or gadoterate?
Radiologists may use other gadolinium-based agents depending on the imaging objective, patient characteristics, institutional protocol, and regulatory labeling. The alternatives generally have broader MRI indications.
Does gadofosveset trisodium have future value in precision vascular imaging?
Any future value would depend on new clinical positioning, manufacturing economics, regulatory work, and demonstrated diagnostic benefit. The historical product record alone does not support a material near-term commercial opportunity.
References
-
U.S. Food and Drug Administration. (2008). Ablavar (gadofosveset trisodium) injection prescribing information. FDA.
-
European Medicines Agency. (n.d.). Vasovist: EPAR and European public assessment information. EMA.
-
Lantheus Medical Imaging, Inc. (2016). Annual report and securities filings. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
European Medicines Agency. (2017). Vasovist marketing authorization withdrawal information. EMA.
